Home/Pipeline/Platform Vaccine Applications

Platform Vaccine Applications

Infectious Diseases

DiscoveryResearch

Key Facts

Indication

Infectious Diseases

Phase

Discovery

Status

Research

Company

Chimeron Bio

About Chimeron Bio

Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Infectious Diseases Rare Genetic Disorders

Other Infectious Diseases Drugs

Drug	Company	Phase	Status
inPROBE Platform	SDS Optic	Early R&D	Active
Potential Human POC Diagnostics	MatMaCorp	Research	Active
Nanoparticle Vaccines	Opko Health	Research	Active
FMN riboswitch modulator	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Pre-Clinical	Exploratory
Ramoplanin™	Nanopharmaceutics	Clinical	Active
NanoDOX™	Nanopharmaceutics	Clinical	Active
Infectious Diseases	Menarini	Clinical	Active
Undisclosed Infectious Disease Program(s)	ATB therapeutics	Pre-clinical	Active
Vaccines for Infectious Diseases (undisclosed)	Takis	Pre-clinical	Active
Infectious Disease Diagnostics Program	Aptus Biosciences	Discovery	Active
Undisclosed Multispecific Therapeutics	ModeX Therapeutics	Pre-clinical	Active